Business
Collaboration with University of Michigan
Collaboration with University of Michigan.
About this update from Theracryf Plc
[{"type":"text","content":"\n \n \n \n Evgen Pharma plc\n \n \n \n (\"Evgen\" or the \"Company\")\n \n \n \n \n \n \n Collaboration with\n \n \n University of Michigan\n \n \n to evaluate SFX-01 in models of colorectal cancer\n \n \n \n \n \n \n \n Alderley Park, UK - 13 June 2022\n \n : Evgen Pharma plc (AIM: EVG), a clinical stage drug development company\n developing sulforaphane-based medicines for the treatment of cancer and other indications\n , announces a collaboration with Dr Grace Chen, of the University of Michigan, to investigate the potential anti-tumour effects of\n the Company's lead asset, SFX-01 in colorectal cancer.\n \n \n \n \n \n SFX-01 is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. Previous studies of the compound have shown in vivo and in vitro efficacy of the compound in a wide range of cancer cells including breast cancer, glioblastoma and certain blood cancers.\n \n \n \n \n \n The collaboration with the University of\n Michigan seeks to evaluate the in vivo effects of SFX-01 in models of colorectal cancer. The effects and mechanism of action of SFX-01 on organoid growth, morphology, stemness and inflammatory markers will also be investigated, using normal and malignant patient-derived organoids and tumour tissue. Initial results are expected at the end of 2023.\n \n \n \n \n \n Colorectal cancer is considered to be the third most common form of cancer worldwide, with between 1.5-2 million annual diagnoses, and second leading cause of cancer-related deaths. There has also been an alarming global rise in early-onset colorectal cancer occurring in individuals under 50 years of age. Treating colorectal cancers can be difficult and does not always lead to cure especially in advanced stages. Therefore, there is a strong need to develop chemoprevention strategies as well as better treatment options.\n \n \n \n \n \n \n \n \n Dr Huw Jones, Evgen CEO, commented:\n \n \n \n \n \"This new project is our fifteenth pre-clinical collaboration to date. Colorectal cancer is a relatively common disease and a cancer type we have not explored extensively. The work of Dr. Chen's group will gain valuable insights into the effects of SFX-01 in models of colorectal cancer. Building on our existing promising data on the mode of action, efficacy and tolerability of ...